Our work shows that there is a molecularly defined subpopulation of CRCs bearing heterozygous mutations in ATM, accounting for up to 12% of patients [42], that may benefit from a combination treatment with niraparib and irinotecan used at low doses, suggesting a new potential approach in the treatment of colorectal cancer. The gene discussed is ATM; the disease is colorectal cancer.